Bristol Myers, Genentech and Celgene bought their old biotechs. Stafford and co. are ready for their next $60M act

Jeffrey Stafford, Ph.D., and his team of industry veterans have seen their biotechs go on to be acquired by the likes of Genentech, Bristol Myers Squibb and Celgene. Now, the collective is ready for its next venture: launching RNA biotech 858 Therapeutics with a $60 million series A fundraising. Backed by founding investor Versant Ventures,…